340B Program's Expansion Now an Earnings Risk

A new research paper in The Milbank Quarterly traces how the 340B drug pricing program grew beyond its original congressional intent, creating pricing distortions that lawmakers now want to unwind. The study, titled "Stretching Scarce Authorizing Legislation as Far as Possible: A Legislative History of the 340B Drug Pricing Program," argues that the expansion has small safety-net initiative into a roughly $40 billion market, according to previous government estimates.

The 340B program requires drugmakers to sell outpatient drugs at steep discounts to hospitals that serve a high share of low-income patients. The original 1992 statute was narrow. The paper details how the Health Resources and Services Administration and hospital groups gradually stretched its language to cover contract pharmacies, child sites, and specialty drugs. That administrative creep turned a targeted subsidy into a broad revenue stream for nonprofit hospital systems.

Reform talks have gained traction in Washington. Bipartisan bills in both chambers would tighten eligibility rules and limit the use of contract pharmacies. A 2023 Supreme Court ruling in American Hospital Association v. Becerra also narrowed the government's ability to impose certain payment cuts tied to 340B. The paper notes that courts have bounced between deferring to agency interpretation and demanding stricter statutory limits, leaving the program's legal footing uncertain.

Hospitals that benefit most include large nonprofit systems with high Medicare and Medicaid patient volumes. Community Health Systems and HCA Healthcare are among those that disclose the program's financial impact in annual filings. A tightening of eligibility rules would reduce a material revenue stream for these operators. Drugmakers like Pfizer and AbbVie have pushed for reform, arguing they are effectively funding hospital profits rather than patient care.

The paper's timing matters. The House Energy and Commerce Committee has held hearings on 340B payment reform. The Centers for Medicare & Medicaid Services has floated changes to how 340B drugs are reimbursed. Neither has produced final rules. The research suggests that the legislative flexibility that fueled the program's growth is now being used to argue for its contraction.

From an earnings perspective, the risk is asymmetric among exposed operators. If reform stalls, current margins hold. If it advances, hospital stocks face headwinds that are not yet priced into consensus estimates. Analysts at multiple investment banks have flagged 340B exposure as a risk factor for community hospital operators. The paper provides the historical context that makes that risk concrete: the program was always vulnerable to reinterpretation, and the political pendulum has swung away from expansion.

The paper does not predict policy outcomes. It maps the legal terrain any reform must cross. That terrain is more constrained than it was a decade ago. Until CMS produces a proposed rule on 340B payment methodology, the uncertainty stays priced into the cost of equity for exposed operators. The next concrete marker is a potential CMS proposed rule, expected later this year.